123 related articles for article (PubMed ID: 31954499)
1. Not All Peritoneal Implants Are Created Equal.
Varghese A; Shih IM
Gynecol Oncol; 2020 Jan; 156(1):1-2. PubMed ID: 31954499
[No Abstract] [Full Text] [Related]
2. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
3. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
4. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
[TBL] [Abstract][Full Text] [Related]
5. Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
Mhawech-Fauceglia P; Izevbaye I; Spindler T; Wang G; Hwang H; Samrao D; Elishaev E; Maxwell GL; Lawrenson K; Darcy KM
Gynecol Oncol; 2020 Jan; 156(1):6-12. PubMed ID: 31711656
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal origin of peritoneal implants and lymph node deposits in serous borderline ovarian tumors (s-BOT) with high intratumoral homogeneity.
Horn LC; Höhn AK; Einenkel J; Siebolts U
Int J Gynecol Pathol; 2014 Nov; 33(6):592-7. PubMed ID: 25272298
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
8. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
9. KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
Heublein S; Grasse K; Hessel H; Burges A; Lenhard M; Engel J; Kirchner T; Jeschke U; Mayr D
BMC Cancer; 2013 Oct; 13():483. PubMed ID: 24139521
[TBL] [Abstract][Full Text] [Related]
10. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
11. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
Ayhan A; Kurman RJ; Yemelyanova A; Vang R; Logani S; Seidman JD; Shih IeM
Am J Surg Pathol; 2009 Aug; 33(8):1220-4. PubMed ID: 19461510
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma.
De Thaye E; Van de Vijver K; Van der Meulen J; Taminau J; Wagemans G; Denys H; Van Dorpe J; Berx G; Ceelen W; Van Bocxlaer J; De Wever O
Sci Rep; 2020 Apr; 10(1):6688. PubMed ID: 32317693
[TBL] [Abstract][Full Text] [Related]
13. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
Shen Y; Yang F; Liu JS
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
[No Abstract] [Full Text] [Related]
14. Borderline papillary serous tumor of the fimbriated end of the fallopian tube with peritoneal implants.
Ondic O; Kalis V; Sima R
J Obstet Gynaecol Res; 2011 Nov; 37(11):1702-5. PubMed ID: 21651651
[TBL] [Abstract][Full Text] [Related]
15. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
16. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
19. Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum.
Hinson SA; Silva EG; Pinto K
Ann Diagn Pathol; 2013 Jun; 17(3):302-4. PubMed ID: 22921726
[TBL] [Abstract][Full Text] [Related]
20. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Farley J; Brady WE; Vathipadiekal V; Lankes HA; Coleman R; Morgan MA; Mannel R; Yamada SD; Mutch D; Rodgers WH; Birrer M; Gershenson DM
Lancet Oncol; 2013 Feb; 14(2):134-40. PubMed ID: 23261356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
